Stephen D. Silberstein, MD, FAHS, FACP Professor of Neurology Jefferson Medical College Thomas Jefferson University Director, Jefferson Headache Center Thomas Jefferson University Hospital Philadelphia, PA
Roger Cady, MD Headache Care Center Springfield, MO
AMA PRA Category 1 Credit™ Medium
Migraine affects between 11% and 16% of adults in the United States. This condition is associated with a significant societal and economic burden. There are many pharmacologic and nonpharmacologic treatment options for both chronic and episodic migraine, and clinicians should tailor these therapies to individual patient characteristics as well as disease severity and patterns. Additionally, patients frequently are not fully adherent to their treatment plan and clinicians should collaborate to increase this adherence. Familiarity with both existing and emerging treatments, as well as patient education techniques, is necessary to improve migraine treatment.
. Target Audience
Primary care clinicians, neurologists, headache specialists, NPs, PAs, nurses, obstetrician/gynecologists, and other clinicians involved in the treatment and management of patients with migraine.
Upon completion of this educational activity, the participant should be able to:
Summarize currently available therapies and delivery systems for migraine treatment and management.
Discuss current evidence on emerging therapies and delivery systems for migraine treatment and management.
List characteristics that are associated with increased risk for poor treatment adherence.
Summarize methods of improving migraine treatment adherence in non-adherent patients.
Stephen D. Silberstein, MD, FAHS, FACP, discloses the following relationships with commercial interests:
Consultant: Alder Biopharmaceuticals, Allergan, Amgen, Avanir Pharmaceuticals, DepoMed, Dr. Reddy's Laboratories, eNeura, ElectroCore, Ipsen Biopharmaceuticals, Medscape, Medtronic, Mitsubishi Tanabe Pharma America, NINDS, St. Jude Medical, Supernus Pharmaceuticals, Teva, Trigemina
Roger Cady, MD, discloses the following relationships with commercial interests:
Consultant: Aerocrine, Allergan, Avanir, Becker Pharma Consulting, DepoMed, Dr. Reddy's Laboratories, Impax Pharmaceuticals, Merck, Teva
Advisory Board: Aerocrine, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, DepoMed, Dr. Reddy's Laboratories, ElectroCore, Merck, Novartis, Optinose, Teva
Speakers Bureau: Allergan, DepoMed, Impax Pharmaceuticals, Merck, Teva
Research Support: Alder Pharmaceuticals, Allergan, Amgen, AstraZeneca, Autonomic Technologies, Avanir, Boston Scientific, Daiichi Sankyo, Dr. Reddy's Laboratories, ElectroCore, Eli Lily, Labrys Biologics, Novartis, Optinose, Pearl Therapeutics, Pharmalyte Solutions, Questcor, Tian Medical, Vivid Pharmaceuticals
Rick Ricer, MD, Physician Reviewer, University of Cincinnati, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CMP, CHCP, FACEHP, University of Cincinnati, has no conflicts of interest to disclose.
Gena Dolson, MCM Education senior medical writer, has no conflicts of interest to disclose.
The University of Cincinnati requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports his presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release date: July 7, 2015
Last review date: July 7, 2015
Expiration date: July 7, 2016 Commercial Support Statements
Supported by an independent educational grant from Teva Pharmaceuticals.
* Link to and Log into program on QuantiaMD.com
* Take the pre-test
* Review the activity
* Take the post-test and score 80%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a CME certificate verifying your
credit/participation in this activity
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
There is no charge for CME credit.
© 2015 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, or Teva. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.